Pulmonary arterial hypertension (PAH) is a rare disease of the small pulmonary arteries for which no cure is available yet. The goal of this project is to model aspects of PAH on a chip allowing for further investigating the disease mechanism and ultimately offering a platform for drug testing. The current approach focusses on mimicking PAH-specific endothelial dysfunction in a three-dimensional hydrogel-based vessel-on-chip using induced pluripotent stem cell-derived vascular cells.
Funding
PHAEDRA-IMPACT consortium